Patents by Inventor Christopher Lee MULLIGAN

Christopher Lee MULLIGAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER
    Publication number: 20210154183
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Inventors: Christopher Lee Mulligan, Justin Blake Bartlett, Michael Darron Robbins
  • Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer
    Patent number: 10925867
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 23, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Christopher Lee Mulligan, Justin Blake Bartlett, Michael Darron Robbins
  • IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER
    Publication number: 20180185348
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: June 28, 2016
    Publication date: July 5, 2018
    Inventors: Christopher Lee MULLIGAN, Justin Blake BARTLETT, Michael Darron ROBBINS